Search

Your search keyword '"Solé Jover, A."' showing total 12 results
Start Over Author "Solé Jover, A." Language english
12 results on '"Solé Jover, A."'

1. darfix – data analysis for dark-field X-ray microscopy

Author

Júlia Garriga Ferrer, Raquel Rodríguez-Lamas, Henri Payno, Wout De Nolf, Phil Cook, Vicente Armando Solé Jover, Can Yildirim, and Carsten Detlefs

Subjects
x-ray optics, software, data analysis, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798, Crystallography, QD901-999
Abstract

A Python package for the analysis of dark-field X-ray microscopy (DFXM) and rocking curve imaging (RCI) data is presented. DFXM is a non-destructive diffraction imaging technique that provides three-dimensional maps of lattice strain and orientation. The darfix package enables fast processing and visualization of these data, providing the user with the essential tools to extract information from the acquired images in a fast and intuitive manner. These data processing and visualization tools can be either imported as library components or accessed through a graphical user interface as an Orange add-on. In the latter case, the different analysis modules can be easily chained to define computational workflows. Operations on larger-than-memory image sets are supported through the implementation of online versions of the data processing algorithms, effectively trading performance for feasibility when the computing resources are limited. The software can automatically extract the relevant instrument angle settings from the input files' metadata. The currently available input file format is EDF and in future releases HDF5 will be incorporated.

Published
2023
Full Text
View/download PDF

2. Evolving Indications for Heart-Lung Transplant in Spain

Author

López-Vilella, Raquel, Gómez Bueno, Manuel, González Vílchez, Francisco, Solé Jover, Amparo, Laporta Hernández, Rosalía, Vicente Guillén, Rosario, González Román, Ana Isabel, Sánchez-Lázaro, Ignacio, Hernández Pérez, Francisco, Sales Badía, Gabriel, Córdoba Peláez, María Del Mar, Torregrosa Puerta, Salvador, Forteza Gil, Alberto, Donoso Trenado, Víctor, Martínez Dolz, Luis, Segovia Cubero, Javier, and Almenar Bonet, Luis

Published
2022
Full Text
View/download PDF

3. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation

Author

Mondejar-Lopez, Pedro, Zolin, Anna, Garcia-Marcos, Patricia W., Pastor-Vivero, Mª Dolores, Rosa-Silvestre, Maria, de Asis Sanchez-Martinez, Francisco, Salvatore, Donatello, Cimino, Giuseppe, Majo, Fabio, Sole-Jover, Amparo, Asensio de la Cruz, Oscar, Calderazzo, Maria Adelaide, Pizzamiglio, Giovanna, Castillo-Corullon, Silvia, Alvarez-Fernandez, Antonio, Gartner, Silvia, Padoan, Rita, Carnovale, Vincenzo, Salvatore, Marco, Moya-Quiles, Mª Rosa, Orenti, Annalisa, Glover, Guillermo, and Sanchez-Solis, Manuel

Published
2022
Full Text
View/download PDF

5. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

Author

Aguilar-Fernández, Antonio J., Andres-Martin, Anselmo, Blanco-Aparicio, Marina, Sirvent-Gomez, Josep, Barajas-Sanchez, Verisima, Baranda, Felix, Gomez-Bonilla, Ainhoa, Bousoño-Garcia, Carlos, Garcia-Clemente, Marta, Bover-Bauza, Catalina, Figuerola-Mulet, Joan, Cabero-Perez, M. Jesús, Iturbe-Fernandez, David, Carrasco-Hernandez, Laura, Delgado-Pecellin, Isabel, Casas-Maldonado, Francisco, Merlos-Navarro, Silvia, Valenzuela-Soria, Alfredo, Cascante-Rodrigo, J. Antonio, Moreno-Galarraga, Laura, Cols-Roig, Maria, de la Cruz, Ofelia Fernandez, Gomez de Terreros, Francisco J., Garcia-Magan, Carlos, Gartner, Silvia, Gomez-Pastrana, David, Gonzalez-Castro, Estela, Jimenez-Nogueira, Esperanza, Herrero-Labarga, M. Ines, de Vicente, Carlos Martín, Juste-Ruiz, Mercedes, Lamas-Ferreiro, Adelaida, Maiz-Carro, Luis, Luna-Paredes, M. Carmen, Mesa-Medina, Orlando, Monton-Soler, Concepcion, Ramos-Hernandez, Cristina, Rodriguez-Saez, M. Jesus, Romero-Albillos, J. Alejandro, Sanz-Santiago, Veronica, Villa-Asensi, J. Ramón, Torres-Borrego, Javier, Vaquero-Barrios, J. Manuel, Velasco-Bernardo, Rosa, Velasco-Gonzalez, Valle, Mondejar-Lopez, Pedro, Quintana-Gallego, Esther, Giron-Moreno, Rosa M., Cortell-Aznar, Isidoro, Ruiz de Valbuena-Maiz, Marta, Diab-Caceres, Layla, Prados-Sanchez, Concepcion, Alvarez-Fernandez, Antonio, Garcia-Marcos, Patricia W., Peñalver-Mellado, Carlos, Pastor-Vivero, M. Dolores, Olveira, Casilda, Lopez-Neyra, Alejandro, Castillo-Corullon, Silvia, Palma-Milla, Samara, Perez-Ruiz, Estela, Sole-Jover, Amparo, Barrio, M. Isabel, Sanchez-Solis, Manuel, and Asensio de la Cruz, Óscar

Published
2020
Full Text
View/download PDF

7. Antifibrotics and lung transplantation: A Spanish multicentre case‐controlled study.

Author

Mora Cuesta, Víctor Manuel, Iturbe Fernández, David, Aguado Ibáñez, Silvia, Anguera de Francisco, Gabriel, Margallo Iribarnegaray, Juan, Carrillo Hernández‐Rubio, Javier, Reig Mezquida, Juan Pablo, Pérez Luz, Virginia, Laporta Hernández, Rosalía, de Pablo Gafas, Alicia, Solé Jover, Amparo, and Cifrián Martínez, José Manuel

Subjects
LUNG transplantation, SURGICAL wound dehiscence, IDIOPATHIC pulmonary fibrosis, KIDNEY transplantation, DRUG standards
Abstract

Background and objective: Antifibrotic drugs are the standard treatments for patients with idiopathic pulmonary fibrosis (IPF). This study aims to assess the safety of antifibrotic treatment in IPF patients undergoing lung transplantation. Methods: Patients with a diagnosis of IPF who received a lung transplant between January 2015 and June 2019 at four Spanish hospitals specialized in lung transplantation were retrospectively recruited. Cases were defined as patients receiving antifibrotic treatments at time of transplant. Each case was matched with a control who did not receive antifibrotic treatment. Results: A total of 164 patients were included in the study cohort (103 cases and 61 controls). There were no statistically significant differences between the cases and controls in any of the items studied related to transplantation except the time until the appearance of chest wall dehiscence: although there were no differences in the incidence of wall dehiscence in either group (12.3% vs. 13.7%; p = 0.318), the patients on antifibrotic drugs experienced it earlier (21 days [IQR = 12.5–41.5] vs. 63 days [IQR = 46.75–152.25]; p = 0.012). There were no differences in overall post‐transplant survival between the two groups (p = 0.698) or in conditional survival at 30 days, 90 days, 3 years or 5 years. However, 1 year survival was significantly greater among controls (80.6% vs. 93.3%; p = 0.028). Conclusion: There was evidence that chest wall dehiscences appeared earlier post‐transplant in patients using antifibrotics, even though this factor did not significantly impact survival. Our findings on the safety of antifibrotic treatment in IPF patients undergoing lung transplantation show that patients receiving antifibrotic treatment at the time of transplantation have similar post‐surgery outcomes to those receiving a lung transplant without antifibrotic treatment, although the adverse effect of chest wall dehiscences in transplant recipients with antifibrotic treatment appeared earlier. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

Author

Bell, Scott C, Reid, David, Wark, Peter, Braeckel, Eva Van, Gohy, Sophie, Knoop, Christiane, Pirson, Jessica, Wachter, Elke De, Dupont, Lieven, Hanssens, Laurence, Nowé, Vicky, Lequesne, Monique, Athanazio, Rodrigo A, Meneses, Daniela G, Boussaud, Véronique, Brinchault, Graziella, Coirier-Duet, Emmanuelle, Dubus, Jean-Christophe, Grenet, Dominique, Miranda, Sandra de, Beaumont, Laurence, Kanaan, Reem, Lauraens, Muriel, Martin, Clémence, Martin, Marie Mittaine, Prévotat, Anne, Reynaud-Gaubert, Martine, Sermet-Gaudelus, Isabelle, Tatopoulos, Aurelie, Chiron, Raphael, Dalphin, Marie-Laure, Gerardin, Michele, Weiss, Laurence, Wizla, Nathalie, Ramel, Sophie, Plant, Barry, Gunaratnam, Cedric, Jackson, Abaigeal, Casciaro, Rosaria, Lucca, Francesca, Daccò, Valeria, Folino, Anna, Manca, Antonio, Messore, Barbara, Morlacchi, Letizia, Pisi, Giovanna, Poli, Piercarlo, Amato, Annalisa, Ferrari, Gianluca, de Winter- de Groot, Karin, Luijk, Bart, Wesseling, Geertjan, Kondratyeva, Elena, Zhekayte, Elena, Amelina, Elena, Mukhina, Mariya, Simonova, Olga, Alvarez-Fernandez, Antonio, Sole-Jover, Amparo, Cortell-Aznar, Isidoro, Giron-Moreno, Rosa, Lopez-Neyra, Alejandro, Ramos-Cancelo, Isabel, Lzaro-Carrasco, Maite, Ruiz de Valbuena, Marta, Prados-Sanchez, Concepcin, Costa-Colomer, Jordi, Gartner, Silvia, Diab-Caceres, Layla, Gilljam, Marita, Lindberg, Ulrika, Diemer, Stefanie, Allenby, Mark, J Bourke, Stephen, C Charman, Susan, Collinson, Janet, Dempsey, Owen, Denniston, Sarah, Desai, Maya, Duckers, Jamie, Etherington, Christine, Gunn, Elaine, Higton, Alex, Ho, Timothy, Hull, Jeremy, Jones, Andrew, Ian Ketchell, Robert, Madge, Susan L., Maitra, Anirban, Mujtaba, Ghulam, Nash, Edward, Nazareth, Dilip, OBrien, Christopher, Onyon, Claire, Orchard, Christopher, Peckham, Daniel, Rodgers, Helen, Shafi, Nadia, Simmonds, Nicholas, Southern, Kevin, Walshaw, Martin, Watson, Danie, L Whitehouse, Joanna, McClenaghan, Elliot, Cosgriff, Rebecca, Brownlee, Keith, Ahern, Susannah, Burgel, Pierre-Régis, Byrnes, Catherine A, Colombo, Carla, Corvol, Harriet, Cheng, Stephanie Y, Daneau, Géraldine, Elbert, Alexander, Faro, Albert, Goss, Christopher H, Gulmans, Vincent, Gutierrez, Hector, de Monestrol, Isabelle, Jung, Andreas, Justus, Lutz Nährlich, Kashirskaya, Nataliya, Marshall, Bruce C, McKone, Edward, Middleton, Peter G, Mondejar-Lopez, Pedro, Pastor-Vivero, M Dolores, Padoan, Rita, Rizvi, Samar, Ruseckaite, Rasa, Salvatore, Marco, Stephenson, Anne L., Filho, Luiz Vicente R da Silva, Melo, Joel, Zampoli, Marco, and Carr, Siobhán B

Published
2020
Full Text
View/download PDF

9. Current Situation and Prognostic Evolution of Combined Heart-lung Transplantation in a European Union Country.

Author

López-Vilella, R., Gómez Bueno, M., González Vílchez, F., Solé Jover, A., Laporta Hernández, R., Vicente Guillén, R., Gonzalez Román, A. I., Sánchez-Lázaro, I., Hernández Pérez, F., Sales Badía, G., Córdoba Peláez, M. D. M., Torregrosa Puerta, S., Forteza Gil, A., Martínez Dolz, L., Segovia Cubero, J., and Bonet, L. Almenar

Subjects
INTERSTITIAL lung diseases, PULMONARY hypertension, EISENMENGER syndrome, PULMONARY arterial hypertension, CYSTIC fibrosis
Abstract

Background: This study aims to evaluate the entire experience in heart-lung transplantation (HLTx) in a country of the European Union with 47 million inhabitants according to the etiologies that motivated the procedure. Methods: A retrospective study on 1,751 consecutive transplants (HLTx: 78) was performed from 1990 to 2020 in two centers. Overall survival, adjusted for clinical profile and etiological subgroups, was compared. 7 subgroups were considered: 1) Cardiomyopathy with pulmonary hypertension (CM + PH). 2) Eisenmenger syndrome. 3) Congenital heart disease (CHD). 4) Idiopathic pulmonary arterial hypertension (IPAH). 5) Cystic fibrosis. 6) Chronic obstructive pulmonary disease (COPD)/Emphysema. 7) Diffuse interstitial lung disease (ILD). Results: Early mortality was 44% and that of the rest of the follow-up was 31%. There were differences between HTLx and HTx in survival, also comparing groups with a similar clinical profile with propensity score (p= 0.04). Median survival was low in CM + PH (18 days), ILD (29 days) and CHD (114 days), intermediate in Eisenmenger syndrome (600 days), and longer in IPAH, COPD/Emphysema and cystic fibrosis. Conclusion: HLTx has a high mortality. The etiological analysis is of the utmost interest to make the most of the organs and improve survival. [ABSTRACT FROM AUTHOR]

Published
2022

12. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

Author

Aguado JM, Silva JT, Fernández-Ruiz M, Cordero E, Fortún J, Gudiol C, Martínez-Martínez L, Vidal E, Almenar L, Almirante B, Cantón R, Carratalá J, Caston JJ, Cercenado E, Cervera C, Cisneros JM, Crespo-Leiro MG, Cuervas-Mons V, Elizalde-Fernández J, Fariñas MC, Gavaldà J, Goyanes MJ, Gutiérrez-Gutiérrez B, Hernández D, Len O, López-Andujar R, López-Medrano F, Martín-Dávila P, Montejo M, Moreno A, Oliver A, Pascual A, Pérez-Nadales E, Román-Broto A, San-Juan R, Serón D, Solé-Jover A, Valerio M, Muñoz P, and Torre-Cisneros J

Subjects
Humans, Postoperative Complications, Anti-Bacterial Agents therapeutic use, Disease Management, Drug Resistance, Multiple, Gram-Negative Bacterial Infections drug therapy, Gram-Negative Bacterial Infections etiology, Gram-Negative Bacterial Infections microbiology, Organ Transplantation, Tissue Donors, Transplant Recipients
Abstract

Solid organ transplant (SOT) recipients are especially at risk of developing infections by multidrug resistant (MDR) Gram-negative bacilli (GNB), as they are frequently exposed to antibiotics and the healthcare setting, and are regulary subject to invasive procedures. Nevertheless, no recommendations concerning prevention and treatment are available. A panel of experts revised the available evidence; this document summarizes their recommendations: (1) it is important to characterize the isolate's phenotypic and genotypic resistance profile; (2) overall, donor colonization should not constitute a contraindication to transplantation, although active infected kidney and lung grafts should be avoided; (3) recipient colonization is associated with an increased risk of infection, but is not a contraindication to transplantation; (4) different surgical prophylaxis regimens are not recommended for patients colonized with carbapenem-resistant GNB; (5) timely detection of carriers, contact isolation precautions, hand hygiene compliance and antibiotic control policies are important preventive measures; (6) there is not sufficient data to recommend intestinal decolonization; (7) colonized lung transplant recipients could benefit from prophylactic inhaled antibiotics, specially for Pseudomonas aeruginosa; (8) colonized SOT recipients should receive an empirical treatment which includes active antibiotics, and directed therapy should be adjusted according to susceptibility study results and the severity of the infection., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results